Valerie Bardet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7310357/publications.pdf

Version: 2024-02-01

56 papers	3,558 citations	236925 25 h-index	175258 52 g-index
58 all docs	58 docs citations	58 times ranked	5355 citing authors

#	Article	IF	Citations
1	Automated Detection of Dysplasia: Data Mining from Our Hematology Analyzers. Diagnostics, 2022, 12, 1556.	2.6	6
2	Perlsâ€™ Stain Guidelines from the French-Speaking Cellular Hematology Group (GFHC). Diagnostics, 2022, 12, 1698.	2.6	0
3	Reticulocytosis As a Whistleblower: A Rare Case of Acquired Elliptocytosis in a Myelodysplastic Syndrome Patient With Trisomy 8. HemaSphere, 2021, 5, e517.	2.7	2
4	Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment. OncoImmunology, 2021, 10, 1945803.	4.6	2
5	Neutrophil Extracellular Traps in SARS-CoV2 Related Pneumonia in ICU Patients: The NETCOV2 Study. Frontiers in Medicine, 2021, 8, 615984.	2.6	16
6	Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1â€tube panel strategy for diagnosis and prognosis of patients with MDS. Cytometry Part B - Clinical Cytometry, 2020, 98, 226-237.	1.5	12
7	Holding on to the Matutes score while dropping FMC7: new opportunity from standardised approaches in multiparameter flow cytometry. British Journal of Haematology, 2020, 190, e255-e258.	2.5	4
8	Platelet Counting: Ugly Traps and Good Advice. Proposals from the French-Speaking Cellular Hematology Group (GFHC). Journal of Clinical Medicine, 2020, 9, 808.	2.4	42
9	Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow. Cell Reports, 2020, 30, 739-754.e4.	6.4	32
10	A hierarchical approach in the diagnostic workflow of chronic myelomonocytic leukemia: Pivotal role of the â€œMonoâ€dysplasiaâ€scoreâ€•combined with flow cytometric quantification of monocyte subsets. International Journal of Laboratory Hematology, 2019, 41, 782-790.	1.3	8
11	The fraction of CD117/câ€KITâ€expressing erythroid precursors predicts ESA response in lowâ€risk myelodysplastic syndromes. Cytometry Part B - Clinical Cytometry, 2019, 96, 215-222.	1.5	10
12	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. Blood Advances, 2019, 3, 4238-4251.	5.2	72
13	CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation. British Journal of Haematology, 2019, 184, 625-633.	2.5	10
14	Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. Haematologica, 2019, 104, 497-504.	3.5	17
15	A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN^{TM} analyzers in routine laboratory practice. Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 159-164.	1.2	14
16	Abstract 1785: Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using Cross-Over-Dual-Variable-Domain (CODV) format for the treatment of acute myeloid leukemia (AML). , 2018, , .		0
17	Harmonisation of full blood count reports, recommendations of the French-speaking cellular haematology group (GFHC). Journal of Clinical Pathology, 2017, 70, 395-402.	2.0	5
18	French Group of Cellular Hematology, Aix en Provence, 17-19ÂMay 2017. Hematologie, 2017, 23, 293-297.	0.0	0

#	Article	IF	Citations
19	Presepsin (sCD14-ST) secretion and kinetics by peripheral blood mononuclear cells and monocytic THP-1 cell line. Annales De Biologie Clinique, 2016, 74, 93-97.	0.1	21
20	APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis. Oncotarget, 2016, 7, 14898-14911.	1.8	11
21	In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. Haematologica, 2015, 100, 223-230.	3.5	58
22	Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica, 2015, 100, 472-478.	3.5	28
23	Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. , 2015, 88, 101-109.		9
24	Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood, 2015, 125, 3618-3626.	1.4	197
25	Full blood count normal reference values for adults in France. Journal of Clinical Pathology, 2014, 67, 341-344.	2.0	63
26	Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. , 2014, , n/a-n/a.		7
27	Sustained Leukemia-Free State and Molecular Response to Sorafenib in a Patient With Chronic Myelomonocytic Leukemia in Transformation Driven by Homozygous FLT3-ITD Malignant Hematopoiesis. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 347-350.	0.4	3
28	Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood, 2013, 122, 3521-3532.	1.4	240
29	High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica, 2011, 96, 1792-1798.	3.5	164
30	A GEIL flow cytometry consensus proposal for quantification of plasma cells: Application to differential diagnosis between MGUS and myeloma. Cytometry Part B - Clinical Cytometry, 2011, 80B, 176-185.	1.5	22
31	Mutual benefits of B-ALL and HLDA/HCDM HLDA 9th Barcelona 2010. Immunology Letters, 2011, 134, 145-149.	2.5	6
32	Leukemic phase of follicular lymphomas: an atypical presentation. Leukemia and Lymphoma, 2011, 52, 1504-1508.	1.3	15
33	Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica, 2010, 95, 415-423.	3.5	129
34	Î²B kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia. Blood, 2010, 116, 4240-4250.	1.4	69
35	The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood, 2010, 116, 4262-4273.	1.4	173
36	Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-Î² signaling at the bipotent erythro-megakaryocytic progenitor stage. Blood, 2010, 115, 2784-2795.	1.4	73

#	Article	IF	Citations
37	Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia, 2010, 24, 1686-1699.	7.2	100
38	Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 5424-5435.	7.0	146
39	Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica, 2010, 95, 819-828.	3.5	240
40	Evaluation of Peroxidase Activity by Alpha-Naphthol/Pyronine Staining Compared with Benzidine Staining in 101 Acute Leukemia Cases. Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology, 2010, 16, 76-82.	1.2	3
41	Targeting translation in acute myeloid leukemia: A new paradigm for therapy?. Cell Cycle, 2009, 8, 3893-3899.	2.6	51
42	Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood, 2009, 114, 1618-1627.	1.4	169
43	PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia, 2008, 22, 1698-1706.	7.2	170
44	Bilateral adrenal chloromas. British Journal of Haematology, 2008, 140, 254-254.	2.5	1
45	Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leukemia and Lymphoma, 2008, 49, 2012-2014.	1.3	23
46	Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood, 2008, 111, 379-382.	1.4	234
47	A critical role for Lyn in acute myeloid leukemia. Blood, 2008, 111, 2269-2279.	1.4	137
48	Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood, 2008, 111, 574-582.	1.4	295
49	Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood, 2007, 110, 1025-1028.	1.4	129
50	Hb Calais [Î²76(E20)Alaâ†'Pro]: A Family Study of a Variant With Decreased Oxygen Affinity. Hemoglobin, 2006, 30, 35-38.	0.8	0
51	Impaired erythropoietin production in liver transplant recipients: The role of calcineurin inhibitors. Liver Transplantation, 2006, 12, 1649-1654.	2.4	18
52	Rational for Specific Inhibition of Both PI3K/AKT and mTORC1 Activities in Acute Myelogenous Leukaemia.. Blood, 2006, 108, 1904-1904.	1.4	1
53	Constitutive Phosphoinositide-3kinase Activation Represents a Good Prognostic Factor in De Novo AML Patients under 60 Years.. Blood, 2006, 108, 1895-1895.	1.4	2
54	Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica, 2006, 91, 757-64.	3.5	41

#	Article	IF	Citations
55	Essential role for the p110Â isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood, 2005, 106, 1063-1066.	1.4	229
56	Molecular analysis of nonrandom 8q12 deletions in acute lymphoblastic leukemia: Identification of two candidate genes. Genes Chromosomes and Cancer, 2002, 33, 178-187.	2.8	10